Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex receives milestone from ImClone
The antibody product, IMC-3G3, was developed using Medarex’s UltiMAb technology and is the second UltiMAb-derived antibody in clinical development by ImClone Systems. US-based Medarex said that the company
The antibody product, IMC-3G3, was developed using Medarex’s UltiMAb technology and is the second UltiMAb-derived antibody in clinical development by ImClone Systems. US-based Medarex said that the company
Picoplatin, the company’s lead product candidate, is a new generation platinum therapy with an improved safety profile. It is designed to overcome and prevent platinum resistance associated with
The Byetta injection will be used specifically for those diabetes patients who have not achieved adequate control on a thiazolidinedione (TZD). In a trial designed to evaluate Byetta
Pending authorization, the phase I/IIa clinical trial of Neugranin will be a safety and tolerability trial in patients with breast cancer. In the first phase of the study,
The phase IIa trial was designed to assess the safety and efficacy of a 28-day treatment course of inhaled Aerovant. The study met its primary endpoint of reducing
The company said patient enrollment in the phase I/II study in the US is expected to start as soon as possible. In addition to the US study, BN
Beta-blockers help to reduce the heart’s workload via their action on beta-adrenergic receptors present in cardiac cells. The single amino acid change in the beta1-adrenergic receptor may differ
Amgen has said the deal with Galapagos could provide it with promising lead candidates for Amgen’s discovery programs over the next two years. Under the terms of the
Exelixis submitted an Investigational New Drug application (IND) for XL518 to the FDA on December 20, 2006. MEK is a key component of a pathway frequently activated in
Lupin Pharmaceuticals, a US subsidiary of Indian-based Lupin Limited, said that final approval is expected upon the expiration of the first abbreviated new drug application filer’s 180-day marketing